लिंकन फार्मास्युटिकल्स शेअर किंमत

Pharmaceuticals company Lincoln Pharmaceuticals announced Q4FY26 & FY26 results Consolidated Financial Highlights: Consolidated total income for Q4FY26 was Rs. 18,308.00 lakh, representing a YoY growth of 13.50% compared to Rs. 16,130.00 lakh in Q4FY25. Consolidated EBITDA for Q4FY26 stood at Rs. 2,066.00 lakh, up 4.13% YoY from Rs. 1,984.00 lakh. Consolidated net profit for Q4FY26 was Rs. 1,163.00 lakh, showing a YoY growth of 0.52% from Rs. 1,157.00 lakh. For the full year FY26, consolidated total income reached Rs. 70,448.00 lakh, a growth of 9.10% YoY compared to Rs. 64,571.00 lakh in FY25. Consolidated EBITDA for FY26 was reported at Rs. 13,114.00 lakh, growing 5.78% YoY from Rs. 12,397.00 lakh in FY25. Consolidated net profit for the full year FY26 reached Rs. 8,789.00 lakh, an increase of 6.74% over Rs. 8,235.00 lakh in FY25. Consolidated EPS for FY26 was reported at Rs. 43.88 per share. Standalone Financial Highlights: Revenue from operations for Q4FY26 stood at Rs. 18,727.73 lakh, representing a YoY increase of 11.35% compared to Rs. 16,818.31 lakh in Q4FY25 and a QoQ increase of 12.60% from Rs. 16,632.20 lakh in Q3FY26. Total income for Q4FY26 was Rs. 18,308.20 lakh, reflecting a YoY growth of 13.50% from Rs. 16,130.34 lakh and a QoQ growth of 0.89% from Rs. 18,146.75 lakh in Q3FY26. Net profit for Q4FY26 reached Rs. 1,163.46 lakh, which is a YoY increase of 0.52% compared to Rs. 1,157.50 lakh in Q4FY25, but a QoQ decline of 59.32% from Rs. 2,860.00 lakh in Q3FY26. For the full year FY26, revenue from operations reached Rs. 67,102.99 lakh, growing 7.67% YoY from Rs. 62,323.01 lakh in FY25. Annual total income for FY26 was Rs. 70,448.39 lakh, an increase of 9.10% over Rs. 64,570.72 lakh in FY25. Annual net profit for FY26 stood at Rs. 8,789.38 lakh, registering a YoY growth of 6.74% from Rs. 8,234.64 lakh in FY25. Earnings Per Share (EPS) for the full year FY26 was Rs. 43.88, compared to Rs. 41.11 in FY25. Business Highlights: Segment Performance: The company operates under a single business segment namely 'Pharmaceutical Business'. Dividend: The Board of Directors has recommended a dividend of 18%, which is Rs. 1.80 per share on the face value of Rs. 10 per share for the year ended March 31, 2026. Growth Targets: The company is targeting a revenue of Rs. 1,00,000 lakh within the next 3 years. It aims to achieve an annual growth rate of 15-18%, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments. International Footprint: The company currently exports to 60+ countries and aims to expand this footprint to 90 countries over the next 2-3 years. It has recently entered the Canadian market and received approvals from TGA - Australia and EU GMP. Product Portfolio: The company has a robust portfolio of over 1,700 registered products, with an additional 700 products currently in the pipeline. Green Energy: The company is nearly a 100% green renewable energy consuming organization, supported by new solar plants at its Mehsana and Khatraj factories, alongside existing windmills. Investment Holdings: As of March 31, 2026, FII holding in the company stood at 5.20% and DII at 1.08%, compared to 5.00% FII holding as of March 31, 2025. Munjal Patel, Director, Lincoln Pharmaceuticals, said: "We are pleased to conclude FY26 on a strong note with healthy growth momentum driven by robust demand, improved operational efficiencies and consistent execution across markets. We remain focused on strengthening our product portfolio, expanding our domestic and international presence and investing in research and manufacturing capabilities. Backed by a debt-free balance sheet and strong fundamentals, we remain confident of sustaining profitable growth and creating long-term value for stakeholders." Result PDF

• ट्रेंडलाईन
• 2 आठवड्यांपूर्वी

उत्पन्न 13% ते 183 कोटी (161 कोटी पासून), तर EBITDA 5% ते 21 कोटी (20 कोटी पासून) पर्यंत वाढले

• बिझनेस लाईन
• 2 आठवडे 3 दिवसांपूर्वी

फार्मास्युटिकल्स कंपनी लिंकन फार्मास्युटिकल्सने Q3FY26 परिणामांची घोषणा केली आहे महसूल: Q3FY25 दरम्यान ₹ 146.55 लाख सापेक्ष ₹ 166.32 लाख, बदल 13%. EBITDA: Q3FY25 दरम्यान ₹ 32.63 लाख सापेक्ष ₹ 38.74 लाख, बदल 19%. पीबीटी: Q3FY25 दरम्यान रु. 28.68 लाख सापेक्ष रु. 34.72 लाख, बदल 21%. पीएटी: Q3FY25 दरम्यान रु. 20.77 लाख सापेक्ष रु. 28.6 लाख, बदला 38%. ईपीएस: Q3FY26 साठी रु. 14.28. लिंकन फार्मास्युटिकल्सचे मॅनेजिंग डायरेक्टर महेंद्र पटेल म्हणाले: "आम्हाला आणखी एक मजबूत तिमाही वितरित करण्यात आनंद होत आहे, जे सर्व बिझनेस व्हर्टिकल्समध्ये सातत्यपूर्ण अंमलबजावणी आणि लवचिक मागणी दर्शविते. आम्ही बायोइक्वलन्स स्टडीज आणि पेटंट उपक्रमांद्वारे समर्थित एकाधिक उपचारात्मक विभाग आणि डोस प्रकारांमध्ये 100 पेक्षा जास्त नवीन विकास कार्यक्रमांसह आमचे संशोधन व विकास; पाईपलाईन मजबूत करीत आहोत. हे प्रयत्न वैज्ञानिक नवकल्पना, पूर्ण न झालेल्या वैद्यकीय गरजा आणि दीर्घकालीन वचनबद्धतेला बळकट करतात. फायदेशीर वाढ. डेब्ट-फ्री बॅलन्स शीट, मजबूत आर&डी; क्षमता आणि निरोगी प्रॉडक्ट पाईपलाईनसह, आम्हाला 15-18% वार्षिक वाढ टिकवून ठेवण्याचा आणि पुढील तीन वर्षांमध्ये आमचे ₹1,000 कोटी महसूल लक्ष्य साध्य करण्याचा विश्वास आहे. "परिणाम पीडीएफ

• ट्रेंडलाईन
• 4 महिन्यांपूर्वी